Mabion S.A. (MAB.WA)
PLN 9.49
(-4.33%)
PLN 9.49
(-4.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -11.98 Million PLN | 74.14% |
| 2022 | -46.35 Million PLN | -63.56% |
| 2021 | -28.34 Million PLN | -182.67% |
| 2020 | 34.28 Million PLN | 668.59% |
| 2019 | -6.03 Million PLN | 88.58% |
| 2018 | -52.78 Million PLN | -181.21% |
| 2017 | 64.99 Million PLN | 3186.09% |
| 2016 | -2.1 Million PLN | 63.95% |
| 2015 | -5.84 Million PLN | 14.8% |
| 2014 | -6.85 Million PLN | -90.16% |
| 2013 | -3.6 Million PLN | 19.85% |
| 2012 | -4.49 Million PLN | 45.37% |
| 2011 | -8.23 Million PLN | 52.86% |
| 2010 | -17.46 Million PLN | -342463.11% |
| 2009 | -5099.63 PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -24.63 Million PLN | -105.46% |
| 2024 Q3 | -45.18 Million PLN | 6.49% |
| 2024 Q2 | -46.31 Million PLN | -88.02% |
| 2023 Q4 | -11.98 Million PLN | 60.63% |
| 2023 Q3 | -30.44 Million PLN | 6.94% |
| 2023 FY | -11.98 Million PLN | 74.14% |
| 2023 Q1 | -62.61 Million PLN | -35.07% |
| 2023 Q2 | -32.71 Million PLN | 47.75% |
| 2022 FY | -46.35 Million PLN | -63.56% |
| 2022 Q4 | -46.35 Million PLN | -680.56% |
| 2022 Q3 | 7.98 Million PLN | 233.54% |
| 2022 Q2 | 2.39 Million PLN | -27.72% |
| 2022 Q1 | 3.31 Million PLN | 111.69% |
| 2021 Q4 | -28.34 Million PLN | 56.72% |
| 2021 Q3 | -65.48 Million PLN | -13.76% |
| 2021 Q2 | -57.56 Million PLN | -386.4% |
| 2021 FY | -28.34 Million PLN | -182.67% |
| 2021 Q1 | 20.09 Million PLN | -41.38% |
| 2020 Q1 | 5.74 Million PLN | 195.29% |
| 2020 FY | 34.28 Million PLN | 668.59% |
| 2020 Q2 | 12.82 Million PLN | 123.23% |
| 2020 Q3 | 23.67 Million PLN | 84.58% |
| 2020 Q4 | 34.28 Million PLN | 44.81% |
| 2019 Q3 | -18.45 Million PLN | 25.77% |
| 2019 Q4 | -6.03 Million PLN | 67.33% |
| 2019 Q2 | -24.86 Million PLN | 30.04% |
| 2019 Q1 | -35.54 Million PLN | 32.66% |
| 2019 FY | -6.03 Million PLN | 88.58% |
| 2018 Q3 | -62.31 Million PLN | -0.14% |
| 2018 FY | -52.78 Million PLN | -181.21% |
| 2018 Q4 | -52.78 Million PLN | 15.3% |
| 2018 Q2 | -62.22 Million PLN | -173.12% |
| 2018 Q1 | 85.1 Million PLN | 30.95% |
| 2017 FY | 64.99 Million PLN | 3186.09% |
| 2017 Q1 | 13.19 Million PLN | 726.31% |
| 2017 Q2 | 29.71 Million PLN | 125.29% |
| 2017 Q3 | 51.42 Million PLN | 73.05% |
| 2017 Q4 | 64.99 Million PLN | 26.39% |
| 2016 FY | -2.1 Million PLN | 63.95% |
| 2016 Q2 | -777 Thousand PLN | 78.14% |
| 2016 Q3 | 35 Thousand PLN | 104.5% |
| 2016 Q4 | -2.1 Million PLN | -6117.14% |
| 2016 Q1 | -3.55 Million PLN | 39.16% |
| 2015 FY | -5.84 Million PLN | 14.8% |
| 2015 Q4 | -5.84 Million PLN | -292.34% |
| 2015 Q3 | -1.48 Million PLN | -8372.22% |
| 2015 Q2 | 18 Thousand PLN | 101.62% |
| 2015 Q1 | -1.11 Million PLN | 83.8% |
| 2014 FY | -6.85 Million PLN | -90.16% |
| 2014 Q4 | -6.85 Million PLN | 63.36% |
| 2014 Q2 | -17.62 Million PLN | -40879.07% |
| 2014 Q1 | -43 Thousand PLN | 98.81% |
| 2014 Q3 | -18.71 Million PLN | -6.2% |
| 2013 Q1 | -372 Thousand PLN | 91.73% |
| 2013 Q2 | -31.78 Million PLN | -8443.82% |
| 2013 Q3 | -10.56 Million PLN | 66.77% |
| 2013 Q4 | -3.6 Million PLN | 65.86% |
| 2013 FY | -3.6 Million PLN | 19.85% |
| 2012 Q4 | -4.49 Million PLN | 15.05% |
| 2012 FY | -4.49 Million PLN | 45.37% |
| 2012 Q3 | -5.29 Million PLN | 0.0% |
| 2011 FY | -8.23 Million PLN | 52.86% |
| 2010 FY | -17.46 Million PLN | -342463.11% |
| 2009 FY | -5099.63 PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | -31.239% |
| BIOTON S.A. | 64.81 Million PLN | 118.499% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 83.331% |
| Molecure S.A. | -56.84 Million PLN | 78.911% |
| NanoGroup S.A. | -537.61 Thousand PLN | -2130.047% |
| Pharmena S.A. | -22.05 Million PLN | 45.643% |
| Poltreg S.A. | -57.75 Million PLN | 79.242% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 228.472% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | 78.979% |
| Synthaverse S.A. | 67.86 Million PLN | 117.665% |
| Urteste S.A. | -512 Thousand PLN | -2241.602% |